Top

Published in:

01-09-2020 | Metastasis | Case Report

Cystic Ileal Gastrointestinal Stromal Tumor Masquerading as Metastatic Adnexal Carcinoma

Authors: Kunal Bikram Deo, Sujan Gautam, Laligen Awale, Tek Narayan Yadav, Anju Pradhan, Narendra Pandit

Published in: Journal of Gastrointestinal Cancer | Issue 3/2020

Excerpt

Gastrointestinal stromal tumors (GIST) are rare, potentially malignant mesenchymal tumor of gastrointestinal tract arising from interstitial cells of Cajal [1]. Stomach is the most common location of GIST (56%), followed by the small intestine (32%), colorectum (6%), and esophagus (< 1%) [1]. Common presentation of the small bowel GIST includes GI bleeding, lump abdomen or non-specific presentations [1, 2]. Frequently, they are encountered by gynecologists as masquerading adnexal tumor, as ileal GIST falls in the pelvis. We describe an interesting case of ileal GIST which mimicked adnexal malignancy with disseminated fleshy peritoneal metastasis. …

Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46. https://doi.org/10.1016/j.canep.2015.10.031.CrossRefPubMed

Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30(4):477–89. https://doi.org/10.1097/00000478-200604000-00008.CrossRefPubMed

Feng F, Wang F, Wang Q, Zheng G, Xu G, Liu S, et al. Clinicopathological features and prognosis of gastrointestinal stromal tumor located in the jejunum and ileum. Dig Surg. 2019;36(2):153–7. https://doi.org/10.1159/000487147.CrossRefPubMed

Carlomagno G, Beneduce P. A gastrointestinal stromal tumor (GIST) masquerading as an ovarian mass. World J Surg Oncol. 2004;2(1):15. https://doi.org/10.1186/1477-7819-2-15.CrossRefPubMedPubMedCentral

Matteo D, Dandolu V, Lembert L, Thomas RM, Chatwani AJ. Unusually large extraintestinal GIST presenting as an abdomino-pelvic tumor. Arch Gynecol Obstet. 2008;278(1):89–92. https://doi.org/10.1007/s00404-007-0528-9.CrossRefPubMed

Zighelboim I, Henao G, Kunda A, Gutierrez C, Edwards C. Gastrointestinal stromal tumor presenting as a pelvic mass. Gynecol Oncol. 2003;91(3):630–5. https://doi.org/10.1016/j.ygyno.2003.08.025.CrossRefPubMed

Xue A, Yuan W, Gao X, Fang Y, Shu P, Xu C, et al. Gastrointestinal stromal tumors (GISTs) with remarkable cystic change: a specific subtype of GISTs with relatively indolent behaviors and favorable prognoses. J Cancer Res Clin Oncol. 2019;145(6):1559–68. https://doi.org/10.1007/s00432-019-02853-y.CrossRefPubMedPubMedCentral

Rubini P, Tartamella F. Primary gastrointestinal stromal tumour of the ileum pre-operatively diagnosed as an abdominal abscess. Mol Clin Oncol. 2016;5(5):596–8. https://doi.org/10.3892/mco.2016.1009.CrossRefPubMedPubMedCentral

Sripathi S, Rajagopal K, Srivastava RK, Ayachit A. CT features, mimics and atypical presentations of gastrointestinal stromal tumor (GIST). Indian J Radiol Imaging. 2011;21(3):176–81. https://doi.org/10.4103/0971-3026.85364.CrossRefPubMedPubMedCentral

10.

Bechtold R, Chen M, Stanton C, Savage P, Levine E. Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. Abdom Imaging. 2003;28(6):808–14. https://doi.org/10.1007/s00261-003-0021-2.CrossRefPubMed

11.

Shi Y-N, Li Y, Wang L-P, Wang Z-H, Liang X-B, Liang H, et al. Gastrointestinal stromal tumor (GIST) with liver metastases: an 18-year experience from the GIST cooperation group in North China. Medicine. 2017;96(46):e8240. https://doi.org/10.1097/MD.0000000000008240.CrossRefPubMedPubMedCentral

12.

Vassos N, Agaimy A, Hohenberger W, Croner RS. Management of liver metastases of gastrointestinal stromal tumors (GIST). Ann Hepatol. 2015;14(4):531–9. https://doi.org/10.1016/S1665-2681(19)31175-5.CrossRefPubMed

13.

Gupta P, Tewari M, Shukla HS. Gastrointestinal stromal tumor. Surg Oncol. 2008;17(2):129–38. https://doi.org/10.1016/j.suronc.2007.12.002.CrossRefPubMed

14.

Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9. https://doi.org/10.1016/j.humpath.2008.06.025.CrossRefPubMed

15.

Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013;20(9):2937–43. https://doi.org/10.1245/s10434-013-3013-7.CrossRefPubMed

16.

Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink H, et al. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol. 2013;39(2):150–5. https://doi.org/10.1016/j.ejso.2012.09.004.CrossRefPubMed

17.

DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, Von Mehren M, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258(3):422–9. https://doi.org/10.1097/SLA.0b013e3182a15eb7.CrossRefPubMedPubMedCentral

18.

Blanke CD, Rankin C, Demetri GD, Ryan CW, Von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626–32. https://doi.org/10.1200/JCO.2007.13.4452.CrossRefPubMed

19.

Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80. https://doi.org/10.1056/NEJMoa020461.CrossRefPubMed

20.

Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol. 2017;8(3):466–73. https://doi.org/10.21037/jgo.2016.09.15.CrossRefPubMedPubMedCentral

21.

Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11(10):942–9. https://doi.org/10.1016/S1470-2045(10)70222-9.CrossRefPubMed

Title: Cystic Ileal Gastrointestinal Stromal Tumor Masquerading as Metastatic Adnexal Carcinoma
Authors: Kunal Bikram Deo
Sujan Gautam
Laligen Awale
Tek Narayan Yadav
Anju Pradhan
Narendra Pandit
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Metastasis
Cancer Biomarker
Gastrointestinal Stromal Tumor
Imatinib
Published in: Journal of Gastrointestinal Cancer / Issue 3/2020
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-020-00403-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2020

Predatory Publishers/Journals in Medical Sciences: How to Avoid, Stop, and What to Do after Being Scammed by Them?

Anticancer Effects of Herbal Medicine Compounds and Novel Formulations: a Literature Review

Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria

Physical Inactivity and Pancreatic Cancer Mortality

Recurrent Overt Gastrointestinal Bleeding from Ulcerated Gastric Elastofibroma: Unprecedented Presentation of a Rare Condition

Delay to Adjuvant Chemotherapy: Survival and Recurrence in Patients of Rectal Cancer Treated with Neo-adjuvant Chemoradiotherapy and Surgery

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials